{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-007972","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.595525+00:00","generated_at":"2026-06-05T06:13:24.809843+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cardiff Oncology: $75M cash, 50% ORR in ONSEMBLE bev naïve, first patient dosed in CRDF-004 trial","bullets":["Cash and equivalents of $75M as of Dec 31, 2023; projected runway into Q3 2025.","ONSEMBLE: 50% ORR (2/4) in bev naïve patients on onvansertib+SoC vs 0% in control; no responses in bev exposed.","First patient dosed in Phase 2 first-line CRDF-004 trial for RAS-mutated mCRC; topline data expected mid-2024.","Pfizer Ignite handling clinical execution; FDA accepted ORR as endpoint for potential accelerated approval.","FY2023 operating expenses $45.9M, net cash used $30.9M; decrease from $33.8M in FY2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-007972","json":"https://secwatch.observer/filing/0001628280-24-007972.json","markdown":"https://secwatch.observer/filing/0001628280-24-007972.md","text":"https://secwatch.observer/filing/0001628280-24-007972.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828024007972/0001628280-24-007972-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828024007972/crdf-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:13:24.809843+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a431ea4b030fad96ca66d05c762841774741899","claim":"Cardiff Oncology, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On February 29, 2024, Cardiff Oncology, Inc. (the “Company”) issued a press release announcing company highlights and financial results for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213037/000162828024007972/0001628280-24-007972-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}